Pioneering novel immunotherapies
through AI-led TCR & antibody design
Powered by cutting-edge drug discovery AI & EXPERIMENTAL validation
PARTNERED WITH
OUR MISSION
Pioneer the combination of machine and human intelligence to develop the best immunotherapies for cancer patients in urgent need
3
TCR and Antibody specific LLMs fine-tuned/created
3
Pipeline programmes
6
In silico design to lead candidates in six months
HOW CAN WE HELP YOU?
Elevate your drug discovery outcomes.
We deliver safer, more precise drug candidates for your pipeline – faster.
How it works
Rapid design & engineering of new candidates and biobetters
Design, optimise and validate TCRs, Antibodies, Bispecifics and VHHs.
See how we engineered a TCR to 5 million fold improvement using our EMLy AI.
See how we supercharge stability and developability of a TCR asset.
Unlock the full potential of your research with EMLy Co-pilot & LLMs
Industry-first TCR and antibody-specific LLMs connected to EMLy co-pilot, empowering scientists with cutting-edge informatics & insights.
Discover how we identify novel targets and therapeutics through the Long term Cancer Survivor Program
Leverage our unmatched scale in deep sequencing, enhanced by EMLy AI error correction, to boost immune repertoire accuracy and align with our exclusive proprietary databases.
Discover how we identify our next target through the Long Term Survivor Programme.
OUR TECHNOLOGY
Introducing EMLy™
The world’s leading repertoire decoding technology specifically built for TCR, Antibodies & Bi-Specifics.
A multi-modality platform
EMLy’s protein language models are designed to be both modality- and disease-agnostic. As solution architects, we recognise that there is no one-size-fits-all approach to protein design—each solution is uniquely tailored to meet specific therapeutic needs.
TCR
Antibody
Bispecific
VHH
OUR STUDY
The Long-term Cancer Survivor Study
Samples
We can access blood and tumour samples, directly or via University of Surrey.
Sequencing
We can deep sequence immune sequence immune repertoires and have databases of 1bn TCRs and 2bn antibodies.
Analysis
We can analyse repertoires with our proprietary LLMs.
Engineering
We can engineer TCRs & antibodies into immune engagers.
INTRODUCING CO-PILOT
Your partner in AI driven drug discovery
OUR PARTNERS
ETCEMBLY PROGRAMS
WHO WE ARE
Meet the team
Michelle Teng
CEO
Co-founder
20 years of experience across pipeline from discovery to translational medicine in Immunocore (KIMMTRAK) & AstraZeneca (FluMist)
Jacob Hurst
CTO
Co-founder
25 years of experience in translational medicine (KIMMTRAK), TCR and antibody repertoire analytics (Abysis)
NICK PUMPHREY
CSO
Over 20 years of experience developing TCR-based therapeutics at Immunocore and Adaptimmune (Afamicel)
BECKIE BOWN
CFO
Over 20 years of finance
experience in biotech/ pharma, including supporting financing transactions and collaborative arrangements
MITHI THAYA
Tech Advisor
Experienced tech
founder with multiple
successful exits
MADHUSHREE GHOSH
Strategy Advisor
Exceptional goal and strategy-driven leader with over twenty-five years’ industry strategic executive leadership experience
JOHN MCCAFFERTY
Scientific Advisor
Serial entrepreneur.
Founder of Cambridge
Antibody Technology,
Maxion Tx, IonTas
NICK CROSS
Chairman
Serial founder and investor
with considerable Board
experience, including
Immunocore,
Adaptimmune, Oxford
Asymmetry and Oxford
Semiconductor Ltd
Bent Jakobsen
Director
TCR therapies pioneer.
Founded Immunocore
and Adaptimmune
< SWIPE TO SEE MORE >
OUR CASE STUDIES
At the forefront of innovation
1
Affinity optimisation
2
Stability and developability
Affinity optimisation
EMLy™ can take TCR/
antibody sequences
and predict affinity
matured variants
Protocol driven molecular docking
...to explore the
complex conformational phase space
High throughput screen of protein variants
Evaluation of
dynamic interactions
Top 50 hit candidate variants selected for validation testing
stability and developability
With EMLy you can
supercharge stability
and developability
of your asset
